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Mini-abstract: 
The validity of self-reported osteoporosis is often questioned, but validation studies are 
lacking. We validated self-reported prevalence and incidence of osteoporosis against self-
reported and administrative data on medications. The concurrent validity was moderate to 
good for self-reported prevalent osteoporosis, but only poor to moderate for self-reported 
incident osteoporosis in mid-age and older women, respectively. Construct validity was 
acceptable for self-reported prevalent but not for incident osteoporosis. 
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Abstract 
Purpose The validity of self-reported osteoporosis is often questioned, but validation 
studies are lacking. The aim was to examine the validity of self-reported prevalence and 
incidence of osteoporosis against self-reported and administrative data on medications. 
Methods Data were from mid-age (56-61 years in 2007) and older (79-84 years in 2005) 
participants in the Australian Longitudinal Study on Women’s Health. Self-reported 
diagnosis was compared with medication information from (1) self-report (nmid=10,509 and 
nold=7,072), and (2) pharmaceutical prescription reimbursement claims (nmid=6,632 and 
nold=4,668). Concurrent validity of self-report was examined by calculating agreement, 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). 
Construct validity was tested by examining associations of self-reported diagnosis with 
osteoporosis-related characteristics (fracture, weight, bodily pain, back pain, and physical 
functioning). 
Results Agreement, sensitivity and PPV of self-reported prevalent diagnosis were 
higher when compared with medication claims (mid-age women: kappa=0.51, 95%CI=0.46-
0.56; older women: kappa=0.65, 95%CI=0.63-0.68) than with self-reported medication (mid-
age women: kappa=0.41, 95%CI=0.37-0.45; older women: kappa=0.57, 95%CI=0.55-0.59). 
Sensitivity, PPV and agreement were lower for self-reported incident diagnosis (mid-age 
women: kappa=0.39, 95%CI=0.32-0.47; older women: kappa=0.55, 95%CI=0.51-0.61). 
Statistically significant associations between self-reported diagnosis and at least four of five 
characteristics were found for prevalent diagnosis in both age groups and for incident 
diagnosis in older women. 
Conclusions  The concurrent validity was moderate to good for self-reported prevalent 
osteoporosis, but only poor to moderate for self-reported incident osteoporosis in mid-age 
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and older women, respectively. Construct validity was acceptable for self-reported prevalent 
but not for incident osteoporosis. 
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Introduction 
Osteoporosis is a disease characterized by low bone mass and micro-architectural 
deterioration of bone tissue leading to enhanced bone fragility and a consequent increase in 
fracture risk [1]. The clinical diagnosis is based on bone densitometry and a bone mineral 
density (BMD) measurement of 2.5 standard deviations or more below the mean for a young 
adult population [1]. However, as it is not feasible to expose all participants to BMD 
measurement, case-definitions of osteoporosis in large scale epidemiological studies and 
national health surveys often rely on self-report of diagnosis, medication or fractures (e.g. [2-
4]).  
 
Sparse evidence suggests moderate agreement between self-report of doctor diagnosed 
osteoporosis and a dual-energy x-ray absorptiometry (DXA) documented osteoporosis 
(kappa=0.43, 95% confidence interval [CI]=0.33-0.53) [5], or a physician’s interpretation of 
medical record information and physical examination (kappa=0.33, CI=0.27-0.39) [6]. Both 
studies were done among adults aged 65 and over. As both under-reporting and over-
reporting of chronic conditions have been associated with increased age [6, 7], results may be 
different for mid-age adults. Although there is some evidence that the validity of self-reported 
diagnosis is poorer for incident than for prevalent diseases [8], validity of self-reported 
incidence of osteoporosis has not been examined before. 
 
The aim of this study was to assess the concurrent and construct validity of self-report of 
prevalent and incident osteoporosis in mid-age and older women. Self-reported diagnosis was 
compared to information about medication use available from self-report as well as the 
Australian pharmaceutical database for prescription reimbursement claims (Pharmaceutical 
Benefits Scheme, PBS) [9]. The main indications for reimbursement of osteoporosis 
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medications include a fragility fracture in people above the age of 70, and BMD T-scores ≤ -
3 measured at two sites, resulting in a high likelihood of prevalent BMD-defined osteoporosis 
in participants with claims. Medication data were used as a reference standard rather than 
medical records or physical examination because of the lack of a centralized medical records 
system in Australia and the remoteness of many of the participants.  
 
Methods 
Study sample 
The Australian Longitudinal Study on Women’s Health (ALSWH) is an ongoing study of 
factors affecting the health and well-being of three population-based cohorts of women born 
in 1973-78, 1946-51, and 1921-26. Recruitment, data collection procedures and attrition have 
been described in more detail elsewhere [10]. In short, women were selected randomly from 
the national Medicare health insurance database which includes all citizens and permanent 
residents of Australia, with oversampling of women living in rural and remote areas to 
capture the heterogeneity in health experiences of women living outside metropolitan areas 
[10]. Baseline characteristics indicated that the sample was reasonably representative of the 
general population of Australian women, although there was overrepresentation of Australia-
born and university educated women [10]. Ethical clearance was obtained from the 
Universities of Newcastle and Queensland and all participants gave signed informed consent. 
Since 1996, mailed surveys have been sent out on a rolling basis generally at 3-year intervals. 
For the current analyses, data were used from surveys 5 and 6 (conducted in 2007 and 2010 
with response rates of 83.8% and 81.6%, respectively) for the mid-age cohort and surveys 4 
and 5 (conducted in 2005 and 2008, with response rates of 83.9% and 79.4%, respectively) 
for the older cohort, as these surveys included self-report of medication. To validate self-
reported prevalent osteoporosis, data were included from the 10,509 mid-age and 7,072 older 
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women who provided self-reported information on osteoporosis and medication at surveys 5 
and 4, respectively. To validate self-reported incident osteoporosis, data were included from 
the 7,118 mid-age women and 2,516 older women who additionally provided self-reported 
information on osteoporosis and medication at surveys 6 and 5, respectively, and who did not 
report having osteoporosis at the previous survey. 
  
Prevalent and incident osteoporosis 
Self-reported osteoporosis: Participants were classified as having prevalent osteoporosis if 
they answered “yes” to the question “In the past three years, have you been diagnosed or 
treated for osteoporosis?” at survey 5 for the mid-age women and survey 4 for the older 
women. Participants without self-reported osteoporosis at survey 5 (mid-age) or 4 (older) and 
who answered “yes” to the question at the subsequent survey three years later, were classified 
as having incident osteoporosis. 
Self-reported osteoporosis medication: In surveys 5 and 6 for the mid-age women and survey 
4 for the older women, participants were asked to copy the names from the packets of all their 
medications, vitamins, supplements or herbal therapies taken in the past four weeks. 
Participants were classified as having prevalent osteoporosis if, they reported at least one of 
the osteoporosis medications listed in Appendix 1 in survey 5 for the mid-age women and 
survey 4 for the older women. Use of Vitamin D however, was not included in this definition 
as supplementation without additional use of other anti-osteoporosis medication is used 
mainly for prevention and is thus less indicative of osteoporosis diagnosis [11]. Participants 
from the mid-age cohort were classified as having incident osteoporosis if they did not report 
medication for osteoporosis at survey 5, but reported at least one of the osteoporosis 
medications listed in Appendix 1 at survey 6. As self-report of medication use was not 
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included in any of the subsequent surveys for the older women, self-reported incident 
osteoporosis medication could not be determined for this cohort. 
Pharmaceutical Benefits Scheme (PBS) recorded osteoporosis medication: PBS is part of the 
Australian government’s broader National Medicines Policy which includes subsidizing the 
costs of medication [9]. PBS records all the prescription medicines that were dispensed with 
Government subsidy. The Scheme is available to all Australian citizens and permanent 
residents. Appendix 1 provides a summary of the osteoporosis medications and the 
indications for which they are subsidized by the PBS. PBS records were linked to ALSWH 
survey data, but only for those participants who consented to linkage (63% and 66% of the 
mid-age and older women, respectively). Participants were classified as having prevalent 
osteoporosis based on PBS data if, in the three years preceding the return date of the relevant 
survey (survey 5 for mid-age women, survey 4 for older women), at least one claim for 
osteoporosis medication was recorded in PBS. Participants were classified as having incident 
osteoporosis if they had not received an osteoporosis medication recorded on the PBS 
database during the three years preceding survey 5 for mid-age women and survey 4 for the 
older women, but did have at least one claim for osteoporosis medication in the PBS database 
in the three years preceding survey 6 for the mid-age women and survey 5 for the older 
women. 
 
Osteoporosis-related characteristics 
The following characteristics were measured using the same methods in all surveys: bodily 
pain and physical functioning were measured as sub scales from the SF-36 [12, 13]. Scores 
ranged from 0 to 100, with higher scores indicating less pain and better physical functioning. 
Fractures were assessed from responses to the question “In the last 12 months, have you 
broken or fractured any bones?” (yes/no). Back pain was assessed with the question “In the 
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last 12 months, have you had back pain: never, rarely, sometimes, or often?” The response 
categories were collapsed into never/rarely vs. sometimes/often. Body weight was preferred 
over body mass index (BMI) as a risk factor for osteoporosis, because BMI may not be a 
reliable indicator of body composition in women with osteoporosis who lose height as a 
result of vertebral deformities and fractures [14].  Furthermore, low BMI is believed to be a 
risk factor for osteoporosis due to reduced loading on the bone, which suggests that weight is 
important rather than the weight to height ratio. Body weight was measured with the question 
“How much do you weigh without clothes or shoes?” (kilograms). 
 
Confounders and effect modifiers 
The associations between self-report of osteoporosis and osteoporosis-related characteristics 
could be confounded by age, level of education, height, chronic conditions, and depressive 
symptoms as these variables have all been found to be associated with either accuracy of self-
report [7, 15] or osteoporosis [16-19], and the osteoporosis-related characteristics [16, 19-23]. 
As memory problems may affect self-report of both osteoporosis diagnosis and medication, 
the validity of self-reported diagnosis of osteoporosis may be different in older women with 
and without memory problems [15]. Memory problems are therefore included as a potential 
effect modifier. All variables were measured using the same methods across surveys unless 
stated otherwise. Height was based on self-report and recorded in centimetres. Education was 
assessed as the highest qualification completed, ranging from “no formal qualification” to 
“university degree or higher”. Chronic conditions were assessed by summing the number of 
reported conditions from the list: diabetes, arthritis, heart disease, stroke, lung disease and 
cancer (range 0-6). In the mid-age cohort, depressive symptoms were assessed using the 10-
item Center for Epidemiologic Studies Depression Scale (CES-D); scores range from 0 to 30 
with higher scores indicating more depressive symptoms [24, 25]. In the older cohort, the 
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Goldberg Anxiety and Depression Scale (GAD) was used [26]; scores range from 0 to 18 
with higher scores indicating more anxiety and depressive symptoms. Memory problems 
were assessed in the older cohort only with the question “In the last 12 months, have you had 
problems with poor memory: never, rarely, sometimes or often?” The categories were 
collapsed into never/rarely vs. sometimes/often. In the older cohort, participants were asked 
to indicate their housing. Response options were collapsed into community-dwelling (ie. 
house, flat/unit/apartment, mobile/caravan, and retirement village) and institutionalized (ie. 
nursing home, hostel, and other). 
 
Statistical analysis 
Sample characteristics were given for both cohorts as means and standard deviations for 
approximately normally distributed continuous variables, as medians and interquartile ranges 
for not normally distributed continuous variables, and as percentages for categorical 
variables. The characteristics of women who consented to data linkage were compared to 
those who did not. Concurrent validity of self-reported prevalent and incident osteoporosis 
was examined by comparing self-reported diagnosis against self-reported medication and 
PBS medication and calculating percentage agreement, bias corrected kappa for chance 
adjusted agreement [27], sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV). To examine the effect of poor memory in the older cohort, the 
analyses were conducted for the total sample was well as for women with and without 
memory problems separately. Kappa-values were interpreted as: poor if <0.40, moderate if 
0.40-0.60, substantial/good if 0.60-0.80, and almost perfect if >0.80 [28]. Construct validity 
of self-reported prevalent and incident diagnosis was examined by testing associations with 
known osteoporosis-related characteristics. The following hypotheses were tested: women 
with osteoporosis have (1) higher fracture risks [29], (2) scores indicating more bodily pain 
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[30], (3) lower weight [29, 31, 32], (4) lower scores for physical functioning [33], and (5) 
more back pain [34] than women without osteoporosis. Logistic regression was used for 
dichotomous characteristics (fractures and back pain), whereas linear regression was used for 
continuous characteristics (weight, bodily pain and physical functioning). Cross-sectional 
models were run for self-reported prevalent diagnosis. For incident diagnosis, associations 
were examined between self-report and change in bodily pain and physical function, and 
incident back pain between the first and follow-up surveys. As weight is a risk factor of 
osteoporosis rather than an outcome [35], associations with this characteristic were assessed 
with weight (dichotomized using <59 kg as the cut-off [35, 36]) as the predictor and self-
reported diagnosis as the outcome. All associations were adjusted for age, education, chronic 
conditions, and depression; the association with weight was additionally adjusted for height. 
Construct validity was considered acceptable if at least four out of five of the hypotheses 
were not rejected [37]. All analyses were done for the two cohorts separately, using STATA 
11.1 (StataCorp LP, College Station, TX). P-values were based on two-sided tests and were 
considered statistically significant at p<0.05. 
 
Results 
The 10,509 and 7,072 women in the mid-age and older cohorts were on average 58.5 (SD 1.5, 
range 53.6-61.9) and 81.2 (SD 1.4, range 77.3-85.5) years old in 2007 and 2005, respectively 
(Table 1). In both cohorts, the majority of the women lived in rural areas and had no or one 
chronic conditions. The proportions of women with prevalent osteoporosis defined from self-
reported diagnosis, self-reported medication and PBS medication were 6.0%, 2.3%, and 3.5% 
in mid-age women, and 22.2%, 16.7%, and 26.0% in older women, respectively. The 
proportions of women with incident osteoporosis over the three years of follow-up defined 
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from self-reported diagnosis, self-reported medication and PBS medication were 3.8%, 2.2%, 
and 1.8% in mid-age women, and 13.4%, (n/a) and 11.5% in older women, respectively.  
 
The prevalent osteoporosis definition based on PBS medication could be derived for 6,632 
mid-age and 4,668 older women who consented to data linkage (Table 1). Among mid-age 
women, those who consented to data linkage were less likely to live in remote areas 
(p<0.001), had higher education levels (p<0.001), and had fewer chronic conditions 
(p=0.003) and depressive symptoms (p<0.001) than those who did not. Among older women, 
those who consented to data linkage were slightly younger (p<0.001), achieved higher 
education levels (p<0.001) and had fewer co-morbidities (p=0.007) than those who did not. 
No statistically significant differences were found in proportions of self-reported diagnosis 
between those who consented to data linkage and those who did not. 
 
Concurrent validity of self-reported diagnosis 
Prevalent osteoporosis 
Table 2 shows the cross-tabulations for self-reported prevalent diagnosis against the self-
reported medication and PBS medication definitions for both cohorts. In mid-age women, 
high percentage agreement was found between self-reported diagnosis and both medication-
based definitions. The chance-adjusted agreement was moderate when self-reported diagnosis 
was compared with self-reported medication (kappa=0.41, CI=0.37-0.45), but higher when 
compared with PBS medication (kappa=0.51, CI=0.46-0.56). Sensitivity, specificity, and 
NPV were good, whereas the PPV was only poor.  
 
In older women, high percentage agreement was found between self-reported diagnosis and 
both medication-based definitions. The chance-adjusted agreement was moderate when self-
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reported diagnosis was compared with self-reported medication (kappa=0.57, CI=0.55-0.59), 
but higher when compared with PBS medication (kappa=0.65, CI=0.63-0.68). Sensitivity and 
PPV were moderate to good, whereas specificity and NPV were good. When sensitivity 
analysis were done for women with and without memory problems, the results were similar 
to those of the total sample with slightly better values in women who reported memory 
problems (self-reported diagnosis against PBS medication: kappa=0.68, CI=0.65-0.71, 
sensitivity=71.8, specificity=93.9, PPV=81.6, NPV=89.7) than in women without memory 
problems (kappa=0.62, CI=0.58-0.66, sensitivity=65.5, specificity=93.3, PPV=76.6, 
NPV=89.0). 
 
Incident osteoporosis 
Table 3 shows the cross-tabulations for self-reported incident diagnosis against the self-
reported medication and PBS medication definitions of osteoporosis for both cohorts. In the 
mid-age cohort, chance-adjusted agreement was poor when self-report was compared with 
self-reported medication (kappa=0.35, CI=0.30-0.45) and PBS medication (kappa=0.39, 
CI=0.32-0.47). As for self-reported prevalent osteoporosis, sensitivity, specificity, and NPV 
were good, but the PPV was only poor. 
 
In the older cohort, percentage agreement between self-reported incident diagnosis and PBS 
medication was high, while the change-adjusted agreement was moderate (kappa=0.55, 
CI=0.51-0.61). Sensitivity and PPV were moderate, but specificity and NPV were good. 
 
Construct validity of self-reported diagnosis 
Prevalent osteoporosis 
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In both cohorts, self-reported prevalent diagnosis was statistically significantly associated 
with all five characteristics (Table 4). Women with self-reported osteoporosis had higher 
risks of fracture and back pain, and lower pain and physical functioning related quality of life 
than women without self-reported osteoporosis. In addition, women with body weight <59 kg 
had higher risks of reporting osteoporosis, compared with those with body weight ≥59 kg. 
 
Incident osteoporosis 
Self-reported incident diagnosis was significantly associated with three out of five 
characteristics in the mid-age women and four out of five characteristics in the older women. 
Women with self-reported osteoporosis had higher fracture risks, higher risk of back pain (in 
older women only), and greater loss of physical functioning related quality of life than 
women without self-reported osteoporosis. In addition, women with body weight <59 kg had 
higher risks of reporting osteoporosis, compared with those with body weight ≥59 kg. 
 
Discussion 
In this study, we examined the validity of self-reported osteoporosis in both mid-age and 
older women against self-reported medication and medication information from the 
Australian pharmaceutical database for prescription reimbursement claims. In both cohorts, 
the chance-adjusted agreement of self-reported prevalent diagnosis with the two medication-
based definitions was moderate to good. Sensitivity, specificity and NPV were good, but PPV 
varied from poor to good depending on the cohort and reference definition used. Sensitivity, 
PPV and chance-adjusted agreement for self-reported incident diagnosis were somewhat 
lower than for self-reported prevalent diagnosis. Construct validity of self-reported prevalent 
diagnoses was acceptable in both the mid-age and older women, whereas construct validity of 
self-reported incident diagnosis was acceptable in the older women only. 
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Concurrent validity of self-reported diagnosis 
The main limitation of this study is lack of the true gold standard for the diagnosis of 
osteoporosis, bone densitometry. However, given the population-based design of the study 
and the fact that over half the sample lived in rural and remote areas where availability of 
DXA scans is scarce [38], exposing all women to a DXA scan is not feasible nor a cost-
effective use of resources. With the linkage of our ALSWH data to the national 
pharmaceutical database, and the strict indications for government subsidy for osteoporosis 
medication (see Appendix 1), we were, in part, able to circumvent this limitation. The main 
indications for PBS subsidy for osteoporosis medications are a fragility fracture in people 
above the age of 70, and BMD T-scores ≤-3 measured at two sites [9]. Subsidised medication 
would not be available to women who did not meet these criteria. It is therefore highly likely 
that women with claims for osteoporosis medication prescription, subsidised by the PBS, 
indeed had been diagnosed with osteoporosis by a physician based on their bone mineral 
density, particularly if the women were under 70. It is well known however, that osteoporosis 
is an underdiagnosed and undertreated condition [34, 38, 39]. The current reference standards 
were based on medication use and thus could not identify women with osteoporosis who did 
not use anti-osteoporosis medication. This may have resulted in underestimation of the 
sensitivity and positive predictive value.  
 
When self-reported prevalent diagnosis was compared with either the self-reported 
medication or the PBS medication definitions, the sensitivity, specificity, and NPV were 
generally good in both cohorts. The low sensitivity in the mid-age women may be explained 
by the strict indications for OP medications in PBS. Women under 70 with BMD T-scores 
between -2.5 and -3 have osteoporosis according to clinical guidelines, but do not meet 
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indications for PBS subsidy benefits and may thus be misclassified in the PBS definition 
(false negatives). In the self-reported medication definition, preventive use of osteoporosis 
medication potentially may have resulted in misclassification in the self-reported medication 
definition (false positives) and subsequently overestimation of the sensitivity. Sensitivity was 
indeed higher when self-reported diagnosis was compared against self-reported medication 
than when compared against PBS medication. In sum, the concurrent validity of self-reported 
diagnosis generally is good, but in mid-age women, sensitivity may be somewhat 
overestimated when compared with the self-reported medication definition and 
underestimated when compared with the PBS medication definition.   
 
The chance adjusted agreement (kappa) was higher when self-reported diagnosis was 
compared with PBS medication than with self-reported medication. This may reflect the fact 
that the PBS medication definition is highly specific (i.e., participants with medication claims 
are highly likely to have been diagnosed with osteoporosis) whereas the self-reported 
medication definition is more inclusive (e.g., includes women in the osteopenic range). 
Values for agreement of self reported diagnosis with medication definitions were higher in 
the current study than in other studies that compared self-report with information from 
medical records [5, 6]. The only study that compared self-report with DXA results found a 
kappa of 0.43 (CI=0.33-0.53) in a sample of 332 women aged 65 to 90 of whom 32% 
reported having osteoporosis [5]. The participants were selected from a larger sample based 
on the availability of DXA results in their medical records. Although other diagnostic values 
were not reported, information was available to calculate sensitivity (62%), specificity (76%), 
PPV (75%) and NPV (80%). Differences in age-range and osteoporosis prevalence may 
explain the slightly lower values compared with the results in our older cohort. In addition, 
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the higher diagnostic values in our study may result from the fact that the PBS definition 
captures the more severe cases, who are more likely to be aware of the diagnosis. 
 
In contrast with our expectations, we found slightly better diagnostic values in older women 
with memory problems than in those without memory problems. Similar results have been 
reported in a study that validated self-reported stroke [15]. A potential explanation could be 
that women with memory problems more often received help from a relative or caregiver 
with the completion of the survey (help received by women with [11%] versus without [9%] 
memory problems, p<0.001). Although statistically significant, differences in diagnostic 
values were only small (≤6 percentage points), suggesting that memory problems minimally 
influenced the concurrent validity of self-reported osteoporosis in older women. 
 
Comparison of the proportions of women with osteoporosis according to the three definitions 
in our study with prevalence rates reported the literature shows that proportions for self-
reported diagnosis were in the same range as those reported in the 2007-08 Australian 
National Health Survey (2.5% in women aged 55-64) [2] and the Australian Bone Care Study 
(25% in 60+ year old women) [34]. However, proportions in our study were about half of the 
BMD measured prevalence rates in the Geelong Osteoporosis Study (2001-06): 8.9% in 55-
59 year old women, and 51.0% in 80+ year old women [40]. The great differences between 
self-reported and BMD measured prevalence rates are likely to be explained by 
underdiagnosis of osteoporosis, particularly in more remote areas of Australia [38]. 
 
In line with results published by Oksanen et al (2011) [8], we found that sensitivity, PPV and 
chance-adjusted agreement were lower for self-reported incident than prevalent diagnosis. 
The agreement was only poor in mid-age women and moderate in older women. Oksanen et 
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al. argue that low sensitivity of self-report potentially leads to underestimation and 
overestimation of associations between risk factors and incident health conditions. Therefore, 
results based on self-reported incidence of diagnosis should be interpreted with care. 
 
Construct validity of self-reported diagnosis 
Self-reported prevalent diagnosis was associated with all five characteristics examined in 
both cohorts, suggesting acceptable construct validity. Construct validity is further supported 
by the finding that the effect sizes reported in this study were similar to those reported in the 
literature. The odds ratios for a fracture in women with self-reported osteoporosis relative to 
those without (mid-age: OR=3.67, older: OR=2.80) were comparable to the relative risks for 
a fracture reported for DXA-determined osteoporosis in the women of the Geelong 
Osteoporosis Study (RR=3.72, CI=2.0-6.9) [41]. In the current study, the odds for reporting 
osteoporosis in women with low body weight was 2.34 (CI=1.92-2.89) in mid-age women 
and 1.51 (CI=1.32-1.73) in older women compared with normal to high body weight women. 
These odds ratios were somewhat higher and lower, respectively, than reported in the Study 
of Osteoporotic Fractures (SOF) including 7782 women aged 65 years and over (OR=2.0, 
CI=1.5-2.7)[36]. These differences in odds ratios are likely to be explained by differences in 
age range of the three cohorts. 
 
Women with self-reported osteoporosis had lower pain and physical functioning related 
quality of life than women without osteoporosis. Studies that compared women with and 
without BMD-measured osteoporosis found no significant differences in these outcomes [42, 
43]. However, these studies compared normal, osteopenic and osteoporotic women, and 
while scores for osteoporotic women did seem worse, differences between normal and 
osteopenic women were minimal. This in addition to the small number of women with 
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osteoporosis may have caused lack of statistically significant overall group differences. 
Alternatively, pain and physical functioning seem to be associated with fractures rather than 
osteoporosis per se [30]. This is particularly true for back pain and vertebral fractures [43]. 
 
Self-reported incident diagnosis was associated with three of the five characteristics in mid-
age women and four of the five outcomes in older women. However, for all characteristics 
the effects were in the expected direction. Lack of statistically significant differences in the 
pain outcomes may have been caused by the low number of incident cases and consequently 
wide confidence intervals. Overall, the results suggest acceptable construct validity of self-
reported incident osteoporosis in both the mid-age and older women. 
 
A strength of the current study is the large sample size. Even though data from only 63% and 
66% of the mid-age and older women could be included for the comparison with PBS 
medication data, our sample sizes were much greater than those reported in similar validation 
studies [5, 6]. Comparison of women who did and those who did not consent to data linkage 
showed that consenters were younger, higher educated and less often lived in remote areas, 
but such differences were only small and would be expected to minimally alter the results. 
Importantly, no differences were found in proportions of self-reported diagnosis between 
those who consented to data linkage and those who did not. The large population-based 
samples, and small differences in characteristics of women who were excluded from the 
current analyses, support the generalizability of the results.  
 
In conclusion, the concurrent validity of self-reported prevalent osteoporosis compared with 
medication data from self-report and the Australian pharmaceutical database for prescription 
reimbursement claims was moderate to good in mid-age and older women. The concurrent 
19 
 
validity of self-reported incident osteoporosis was only poor in mid-age women and moderate 
in older women. Construct validity was acceptable for self-reported prevalent but not for 
incident osteoporosis. 
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Table 1. Characteristics for the total sample, and for women who did and did not consent to data linkage separately 
 Mid-age women (2007) Older women (2005) 
 Total sample Consent No consent p
a
 Total sample Consent No consent p
a
 
N 10509 6632 3877  7072 4668 2404  
Self-reported prevalence (%) 6.0 6.0 6.0 0.99 22.2 22.8 21.0 0.06 
Self-reported incidence (%) 3.8 3.7 3.8 0.89 13.4 13.9 12.2 0.15 
Age (mean (SD)) 58.5 (1.5) 58.5 (1.5) 58.5 (1.5) 0.21 81.2 (1.4) 81.2 (1.4) 81.3 (1.5) <0.001 
Area (%)    <0.001    0.44 
Urban 39.0 38.9 39.1  43.9 43.9 44.0  
Rural 56.2 57.3 54.4  54.0 54.2 53.6  
Remote 4.8 3.8 6.5  2.1 1.9 2.4  
Level of education (%)    <0.001    <0.001 
No formal qualification 16.4 13.5 21.5  30.0 28.6 39.1  
School certificate 31.6 31.6 31.6  39.8 40.1 37.1  
Higher school certificate 16.7 16.7 16.8  13.2 13.2 11.9  
Trade/apprentice/certificate 20.2 21.4 18.1  12.5 13.1 9.4  
University degree or higher 15.0 16.7 12.1  4.6 5.0 2.5  
Co-morbidities (median [IQR]) 1 [0-1] 1 [0-1] 1 [0-1] 0.003 1 [1-2] 1 [0-2] 1 [1-2] 0.007 
Depressive symptoms (median [IQR])
b 
4 [2-8] 4 [2-8] 5 [2-9] <0.001 5 [2-8] 5 [2-8] 5 [3-9] 0.11 
Memory problems (%) -    50.7 52.6 47.1 <0.001 
Living in the community (%) -    97.5 97.7 97.1 0.17 
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SD = Standard Deviation, IQR = Interquartile Range 
a
 p-values for differences between women who did and did not consent to data linkage. 
b
 Assessed with the 10-item CESD in mid-age women (range 0-30) and the Goldberg Anxiety Depression scale in older women (range 0-18). 
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Table 2. Concurrent validity: self-reported prevalent osteoporosis compared with osteoporosis definitions based on self-reported medication and 
Pharmaceutical Benefits Scheme (PBS) prescription reimbursement claims 
  
Mid-age women (2007)  Older women (2005) 
  
Self-reported  OP 
medication 
 
PBS claims for OP 
medication  
Self-reported  OP 
medication  
PBS claims for OP 
medication 
  
OP no OP 
 
OP no OP  OP no OP  OP no OP 
self-report 
 
 
    
      
OP 
 
187 439 
 
166 229  895 673  847 219 
no OP 
 
51 9832 
 
59 6178  284 5220  384 3218 
  
    
 
              
Agreement 
 
95.3   
 
95.7    86.5    87.1   
Kappa 
 
0.41 (0.37-0.45) 
 
0.51 (0.46-0.56)  0.57 (0.55-0.59)  0.65 (0.63-0.68) 
Sensitivity 
 
78.6 (72.8-83.6) 
 
73.8 (67.5-79.4)  75.9 (73.4-78.3)  68.8 (66.1-71.4) 
Specificity 
 
95.7 (95.7-96.1) 
 
96.4 (95.9-96.9)  88.6 (87.7-89.4)  93.6 (92.8-94.4) 
PPV 
 
29.9 (26.3-33.6) 
 
42.0 (37.1-47.1)  57.1 (54.6-59.5)  79.5 (76.9-81.8) 
NPV 
 
99.5 (99.3-99.6) 
 
99.1 (98.8-99.3)  94.8 (94.2-95.4)  89.3 (88.3-90.3) 
OP = osteoporosis, PPV = Positive Predictive Value, NPV = Negative Predictive Value 
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Table 3. Concurrent validity: self-reported incident osteoporosis compared with self-reported medication and Pharmaceutical Benefits Scheme 
(PBS) subsidised OP medication. 
  
Mid-age women (2007-2010)  Older women (2005-2008) 
  
Self-reported  OP 
medication 
 
PBS claims for OP 
medication 
 PBS claims for OP 
medication 
 
  
OP no OP 
 
OP no OP  OP no OP  
self-report 
      
    
OP 
 
67 207 
 
63 153  182 99  
no OP 
 
30 6814 
 
33 5521  137 2098  
       
    
Agreement 
 
96.7 
  
96.8 
 
 90.6   
Kappa 
 
0.35 (0.30- 0.45) 
 
0.39 (0.32-0.47)  0.55 (0.51-0.61)  
Sensitivity 
 
69.1 (58.9-78.1) 
 
65.6 (55.2-75.0)  57.1 (51.4-62.6)  
Specificity 
 
97.1 (96.6-97.4) 
 
97.3 (96.8-97.7)  95.5 (94.5-96.3)  
PPV 
 
24.5 (19.5-30.0) 
 
29.2 (23.2-35.7)  64.8 (58.9-70.3)  
NPV 
 
99.6 (99.4-99.7) 
 
99.4 (99.2-99.6)  93.9 (92.8-94.8)  
OP = osteoporosis, PPV = Positive Predictive Value, NPV = Negative Predictive Value 
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Table 4. Construct validity: associations between self-reported incident osteoporosis (OP) and osteoporosis-related characteristics 
  Fracture
 
Bodily pain
 
Back pain
 
Physical functioning
 
Weight 
  OR CI Δ CI OR CI Δ CI OR CI 
Mid-age women   
   
  
 
  
Self-reported prevalent OP 3.63 (2.78 to 4.75) -3.16 (-4.88 to -1.45) 1.35 (1.13 to 1.62) -2.76 (-4.24 to -1.28) 2.34 (1.92 to 2.89) 
Self-reported incident OP 5.69 (4.09 to 7.91) -2.14 (-4.54 to 0.27) 1.10 (0.79 to 1.53) -2.80 (-4.56 to -1.03) 1.95 (1.47 to 2.58) 
Older women   
   
  
 
  
Self-reported prevalent OP 2.74 (2.23 to 3.38) -6.13 (-7.50 to -4.77) 1.93 (1.66 to 2.24) -5.32 (-6.83 to -3.83) 1.51 (1.32 to 1.73) 
Self-reported incident OP 2.89 (2.12 to 3.95) -1.23 (-3.51 to 1.05) 1.53 (1.15 to 2.04) -3.19 (-5.38 to -0.99) 1.68 (1.36 to 2.09) 
Women with and without self-reported osteoporosis were compared on five osteoporosis-related characteristics. Presented are the odds ratios 
(OR) from logistic regression for dichotomous outcomes and the differences in mean scores (Δ) from linear regression for continuous outcomes 
and 95% confidence intervals (CI) after adjustment for age, education, chronic conditions and depression. As low weight is a risk factor for OP, 
this association was tested using logistic regression with weight (<59 kg vs. ≥59 kg) as the predictor and OP as the outcome; adjustment was 
made for age, education, chronic conditions, depression and height. Cross-sectional models were used for prevalent OP, whereas longitudinal 
models were used for incident OP with fractures at follow-up, incident back pain, and change in bodily pain and physical functioning as the 
outcomes. Negative scores for bodily pain and physical functioning indicate poorer quality of life (prevalent OP) and greater decline in quality of 
life (incident OP) resulting from pain and functional limitations, respectively.  
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Appendix 1. Overview of osteoporosis medication claims in the Pharmaceutical Benefits 
Scheme (PBS) 
Class names generic names ATC codes PBS item numbers  Indications 
for benefits 
Bisphosphonates Alendronate M05BA04 8511Y  1,2,3 
   M05BB03 9012H, 9183H 1,2,3 
   M05BB05 9351E 1,2,3 
 Zoledronic acid M05BA08 9288W 1,2,3 
 Risedronate M05BA07 4443W, 4444X 4 
  M05BA07 8481J, 8621R, 8972F, 9391G 1,2.3 
  M05BB02 8899J, 8973G, 4059P 1,2,3 
   M05BB04 9147K, 8974H, 4380M 1,2,3 
 Disodium etidronate M05BB01 8056B 3 
Other Strontium ranelate M05BX03 3036T 2,3 
 Denosumab M05BX04 5457F 2,3 
Parathyroid hormone Teriparatide H05AA02 9411H 5 
SERM Raloxifene G03XC01 8363E 3 
Vitamin D Ergocalciferol A11CC01 6834M 6 
 Calcitriol A11CC04 2502Q 6 
 Colecalciferol A11CC05 9191N, 9223G, 9859R 6 
SERM = Selective Estrogen Receptor Modulator 
Summary of indications for PBS benefits (more details can be found on 
http://www.pbs.gov.au/browse/body-system): 
1. Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced 
osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 
7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a BMD T-score of 
-1.5 or less.  
2. Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient 
aged 70 years or older with a BMD T-score of -3.0 or less.  
3. Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in 
patients with fracture due to minimal trauma.  
4. For preservation of BMD in patients on long-term glucocorticoid therapy where patients 
are undergoing continuous treatment with a dose equal to or greater than 7.5 mg of 
prednisone or equivalent per day. Prescribers need to demonstrate that the patient has 
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been on continuous therapy for 3 months or more and demonstrate that the patient is 
osteopenic (bone mineral density t-score of less than -1.0). 
5. One of following three indications: 
5.1. Initial treatment, as the sole PBS-subsidised agent, by a specialist or consultant 
physician, for severe, established osteoporosis in a patient with a very high risk of 
fracture who:  
(a) has a bone mineral density (BMD) T-score of -3.0 or less; and  
(b) has had 2 or more fractures due to minimal trauma; and  
(c) has experienced at least 1 symptomatic new fracture after at least 12 months 
continuous therapy with an anti-resorptive agent at adequate doses.  
5.2. Initial treatment, as the sole PBS-subsidised agent, by a specialist or consultant 
physician, for severe, established osteoporosis in a patient with a very high risk of 
fracture who was receiving treatment with teriparatide prior to 1 May 2009.  
5.3. Continuing treatment for severe established osteoporosis where the patient has 
previously been issued with an authority prescription for this drug. 
6. Treatment for established osteoporosis in patients with fracture due to minimal trauma. 
 
Additional notes: 
Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate 
sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and 
zoledronic acid.  
 
Minimal trauma fractures must have been demonstrated radiologically and the year of plain 
x-ray or CT-scan or MRI scan must be documented in the patient's medical records when 
treatment is initiated.  
 
A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid 
portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater 
reduction in any of these heights compared to the vertebral body above or below the affected 
vertebral body. 
 
